Shu Utsumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shu Utsumi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Nobuaki Shime
8 shared publicationsShingo Ohki
5 shared publicationsShunsuke Amagasa
Department of Emergency and Transport Medicine, National Center for Child Health and Development, Tokyo, Japan
5 shared publicationsSatoko Uematsu
Department of Emergency and Transport Medicine, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan
4 shared publicationsHiroyuki Suzuki
Advanced Medical Emergency Department and Critical Care Centre, Maebashi Red Cross Hospital, Gunma, Japan
3 shared publicationsShinichiro Ohshimo
Department of Emergency and Critical Care Medicine, Hiroshima University Faculty of Medicine Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
3 shared publications
Latest Publications
- 24 June 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
Association between the fresh frozen plasma-to-red blood cell ratio and mortality in pediatric severe trauma
BACKGROUND: The optimal fresh frozen plasma (FFP)-to-red blood cell (RBC) ratio in pediatric severe trauma has not yet been established. We investigated the association between the FFP-to-RBC transfusion ratio and clinical outcomes in pediatric severe trauma, aiming to identify an optimal threshold. METHODS: This multicenter, retrospective, observational study uses data from the Japan Trauma Data Bank from 2019 to 2023. The study included pediatric patients aged below 18 years with severe trauma (injury severity score >15). Patients were categorized into a high-FFP group (FFP-to-RBC ratio ≥1) and a low-FFP group (ratio of J Trauma Acute Care Surg 2026;00:000–000. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Therapeutic/care management; Level III.
- 24 June 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
Association between the fresh frozen plasma-to-red blood cell ratio and mortality in pediatric severe trauma
BACKGROUND: The optimal fresh frozen plasma (FFP)-to-red blood cell (RBC) ratio in pediatric severe trauma has not yet been established. We investigated the association between the FFP-to-RBC transfusion ratio and clinical outcomes in pediatric severe trauma, aiming to identify an optimal threshold. METHODS: This multicenter, retrospective, observational study uses data from the Japan Trauma Data Bank from 2019 to 2023. The study included pediatric patients aged below 18 years with severe trauma (injury severity score >15). Patients were categorized into a high-FFP group (FFP-to-RBC ratio ≥1) and a low-FFP group (ratio of J Trauma Acute Care Surg 2026;00:000–000. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.) LEVEL OF EVIDENCE: Therapeutic/care management; Level III.
- 25 February 2026
- Published by BMJ in Emergency Medicine Journal
- Vol. 43 (5) , 298-304
Sequence of advanced airway management and epinephrine administration for paediatric patients with non-shockable out-of-hospital cardiac arrest
Background Despite the frequent use of both advanced airway management (AAM) and epinephrine during resuscitation, no studies have evaluated the optimal sequencing of these interventions in paediatric out-of-hospital cardiac arrest (OHCA). We therefore aimed to investigate the association between the sequence of AAM and epinephrine administration and outcomes in paediatric patients with OHCA with non-shockable rhythms. Methods This retrospective observational study analysed data from a multicentre OHCA registry in Japan from 2014 to 2022. We included paediatric patients (aged Results Of the 952 paediatric patients with non-shockable OHCA (median age (IQR) 2 (0–14) years), 577 (61%) were male. Of these, 455 and 497 belonged to the AAM-first and epinephrine-first groups, respectively. After IPTW, all covariates were well balanced between the AAM-first and epinephrine-first groups (standardised mean difference ≤0.10). Compared with the epinephrine-first group, the AAM-first group showed similar 1-month survival (adjusted OR (aOR), 1.09; 95% CI 0.61 to 1.86), favourable neurological outcome at 1 month (aOR, 0.79; 95% CI 0.12 to 5.07) and ROSC (aOR, 0.98; 95% CI 0.72 to 1.35). Conclusions The sequence of AAM and epinephrine administration was not associated with 1-month survival, favourable neurological outcome at 1 month or ROSC in paediatric patients with non-shockable OHCA.
- 25 February 2026
- Published by BMJ in Emergency Medicine Journal
- Vol. 43 (5) , 298-304
Sequence of advanced airway management and epinephrine administration for paediatric patients with non-shockable out-of-hospital cardiac arrest
Background Despite the frequent use of both advanced airway management (AAM) and epinephrine during resuscitation, no studies have evaluated the optimal sequencing of these interventions in paediatric out-of-hospital cardiac arrest (OHCA). We therefore aimed to investigate the association between the sequence of AAM and epinephrine administration and outcomes in paediatric patients with OHCA with non-shockable rhythms. Methods This retrospective observational study analysed data from a multicentre OHCA registry in Japan from 2014 to 2022. We included paediatric patients (aged Results Of the 952 paediatric patients with non-shockable OHCA (median age (IQR) 2 (0–14) years), 577 (61%) were male. Of these, 455 and 497 belonged to the AAM-first and epinephrine-first groups, respectively. After IPTW, all covariates were well balanced between the AAM-first and epinephrine-first groups (standardised mean difference ≤0.10). Compared with the epinephrine-first group, the AAM-first group showed similar 1-month survival (adjusted OR (aOR), 1.09; 95% CI 0.61 to 1.86), favourable neurological outcome at 1 month (aOR, 0.79; 95% CI 0.12 to 5.07) and ROSC (aOR, 0.98; 95% CI 0.72 to 1.35). Conclusions The sequence of AAM and epinephrine administration was not associated with 1-month survival, favourable neurological outcome at 1 month or ROSC in paediatric patients with non-shockable OHCA.
- 5 September 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (10) , e1310-e1311
Isolated Moderate Pediatric Traumatic Brain Injury in Japan, 2019–2024
- 5 September 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (10) , e1310-e1311
Isolated Moderate Pediatric Traumatic Brain Injury in Japan, 2019–2024
- 7 August 2025
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 19, e223
Impact of the 2018 Western Japan Heavy Rain Disaster on Anti-influenza Virus Drug Prescribing: A Longitudinal Analysis Using the National Health Insurance Claims Database
Objectives: No study has evaluated the relationship between heavy rain disasters and influenza by comparing victims and non-victims, and we investigated the association between the 2018 western Japan heavy rain disaster and influenza. Methods: All patients registered in the National Health Insurance Claims Database and treated in the Hiroshima, Okayama, and Ehime prefectures were included in this retrospective cohort study conducted 1-year post-disaster. A multivariate mixed-effects logistic regression analysis was used to assess the association between the disaster and anti-influenza drug prescribing. A difference-in-differences analysis was conducted to assess anti-influenza drug use for the 4-month period immediately before and every 4 months for a year post-disaster. Results: This study included 6 176 300 individuals (victims: 36 076 [0.60%]); 2573 (7.1%) and 458 157 (7.4%) in the victim and non-victim groups, respectively, used anti-influenza drugs in the year following the flood. The victims were significantly more likely than non-victims to use anti-influenza drug (risk ratio 1.18; 95% confidence interval [CI] 1.12-1.42). The victims used significantly more anti-influenza drugs in the 4 months immediately post-disaster compared with just before the disaster (odds ratio 3.62; 95% CI 1.77-7.41). Conclusions: Anti-influenza drug use was higher among victims of the 2018 Western Japan heavy rain disaster than among non-victims.
- 7 August 2025
- Published by Cambridge University Press (CUP) in Disaster Medicine and Public Health Preparedness
- Vol. 19, e223
Impact of the 2018 Western Japan Heavy Rain Disaster on Anti-influenza Virus Drug Prescribing: A Longitudinal Analysis Using the National Health Insurance Claims Database
Objectives: No study has evaluated the relationship between heavy rain disasters and influenza by comparing victims and non-victims, and we investigated the association between the 2018 western Japan heavy rain disaster and influenza. Methods: All patients registered in the National Health Insurance Claims Database and treated in the Hiroshima, Okayama, and Ehime prefectures were included in this retrospective cohort study conducted 1-year post-disaster. A multivariate mixed-effects logistic regression analysis was used to assess the association between the disaster and anti-influenza drug prescribing. A difference-in-differences analysis was conducted to assess anti-influenza drug use for the 4-month period immediately before and every 4 months for a year post-disaster. Results: This study included 6 176 300 individuals (victims: 36 076 [0.60%]); 2573 (7.1%) and 458 157 (7.4%) in the victim and non-victim groups, respectively, used anti-influenza drugs in the year following the flood. The victims were significantly more likely than non-victims to use anti-influenza drug (risk ratio 1.18; 95% confidence interval [CI] 1.12-1.42). The victims used significantly more anti-influenza drugs in the 4 months immediately post-disaster compared with just before the disaster (odds ratio 3.62; 95% CI 1.77-7.41). Conclusions: Anti-influenza drug use was higher among victims of the 2018 Western Japan heavy rain disaster than among non-victims.
- 8 June 2025
- Published by BMJ in Archives of Disease in Childhood
Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis
Objective To evaluate the efficacy differentials among corticosteroid regimens by type, dosage and duration, we conducted a systematic review and network meta-analysis of randomised controlled trials (RCTs). Methods We searched four databases from their inception to March 2024 and included RCTs that evaluated oral corticosteroids for asthma exacerbations in young people aged Results Eleven studies involving 2353 patients were analysed in our quantitative synthesis. There were no significant differences in the relapse rates among 15 comparisons of six regimens. As part of the results, the network estimate showed that DEXA (0.3 mg/kg/day×1 day) compared with PSL (1.0 mg/kg/day for 3 days) had a risk ratio (RR) of 0.99 (95% CI 0.56 to 1.74), and DEXA (0.6 mg/kg/day for 2 days) compared with PSL (1.0–1.5 mg/kg/day×5 days) had an RR of 1.29 (95% CI 0.84 to 1.98). The certainty of the evidence for the included comparisons was low to very low. Conclusion In this network meta-analysis, there were no significant differences in the efficacy of commonly used corticosteroid regimens for acute exacerbations in childhood asthma. Short-term oral DEXA may be an acceptable alternative to a longer course of PSL. PROSPERO registration number CRD 42023449189.
- 8 June 2025
- Published by BMJ in Archives of Disease in Childhood
Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis
Objective To evaluate the efficacy differentials among corticosteroid regimens by type, dosage and duration, we conducted a systematic review and network meta-analysis of randomised controlled trials (RCTs). Methods We searched four databases from their inception to March 2024 and included RCTs that evaluated oral corticosteroids for asthma exacerbations in young people aged Results Eleven studies involving 2353 patients were analysed in our quantitative synthesis. There were no significant differences in the relapse rates among 15 comparisons of six regimens. As part of the results, the network estimate showed that DEXA (0.3 mg/kg/day×1 day) compared with PSL (1.0 mg/kg/day for 3 days) had a risk ratio (RR) of 0.99 (95% CI 0.56 to 1.74), and DEXA (0.6 mg/kg/day for 2 days) compared with PSL (1.0–1.5 mg/kg/day×5 days) had an RR of 1.29 (95% CI 0.84 to 1.98). The certainty of the evidence for the included comparisons was low to very low. Conclusion In this network meta-analysis, there were no significant differences in the efficacy of commonly used corticosteroid regimens for acute exacerbations in childhood asthma. Short-term oral DEXA may be an acceptable alternative to a longer course of PSL. PROSPERO registration number CRD 42023449189.
- 21 May 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 95, 173-178
Efficacy of tranexamic acid in adult isolated traumatic brain injury: A multicenter retrospective study
- 21 May 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 95, 173-178
Efficacy of tranexamic acid in adult isolated traumatic brain injury: A multicenter retrospective study
- 6 December 2024
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 98 (5) , 816-823
Optimal dose of tranexamic acid in traumatic brain injury: Systematic review and network meta-analysis of randomized controlled trials
BACKGROUND Tranexamic acid (TXA) has been used to treat traumatic brain injury (TBI); however, no definitive conclusions have been drawn regarding its effectiveness or dosage. This study evaluated the optimal TXA dose for treating TBI using a network meta-analysis (NMA). METHODS Five databases were searched for peer-reviewed randomized controlled trials (RCTs) published from inception to May 2024. The inclusion criteria were as follows: (1) RCTs, (2) patients older than 1 month with TBI, (3) interventions of TXA and control, (4) primary outcomes of mortality and poor neurological outcomes and secondary outcomes of vascular occlusive events, and (5) full-text peer-reviewed articles. Two reviewers independently screened and extracted the data and assessed the risk of bias. Frequency-based NMA was performed using the Grading of Recommendations, Assessment, Development, and Evaluation working-group approach. RESULTS We included 10 RCTs comprising 11,237 patients with TBI. Placebo showed higher mortality compared with that of a 2-g bolus of TXA (risk ratio, 1.53; 95% confidence interval, 1.08–2.17). Higher mortality was observed with a 1-g bolus of TXA followed by 1-g maintenance TXA compared with that of a 2-g bolus of TXA (risk ratio, 1.44; 95% confidence interval, 1.02–2.03). No significant differences in poor neurological outcomes or vascular occlusive events were observed between the treatment groups. CONCLUSION Placebo and a 1-g bolus followed by 1-g maintenance TXA were associated with higher mortality rates than those of a 2-g bolus of TXA. No difference in vascular occlusive events was observed with either treatment, indicating that our NMA recommends 2 g of TXA. However, the data for the 2-g bolus of TXA were from a single study, and further research is needed to draw definitive conclusions. LEVEL OF EVIDENCE Systematic Review/Meta-Analysis; Level III. Export
- 6 December 2024
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 98 (5) , 816-823
Optimal dose of tranexamic acid in traumatic brain injury: Systematic review and network meta-analysis of randomized controlled trials
BACKGROUND Tranexamic acid (TXA) has been used to treat traumatic brain injury (TBI); however, no definitive conclusions have been drawn regarding its effectiveness or dosage. This study evaluated the optimal TXA dose for treating TBI using a network meta-analysis (NMA). METHODS Five databases were searched for peer-reviewed randomized controlled trials (RCTs) published from inception to May 2024. The inclusion criteria were as follows: (1) RCTs, (2) patients older than 1 month with TBI, (3) interventions of TXA and control, (4) primary outcomes of mortality and poor neurological outcomes and secondary outcomes of vascular occlusive events, and (5) full-text peer-reviewed articles. Two reviewers independently screened and extracted the data and assessed the risk of bias. Frequency-based NMA was performed using the Grading of Recommendations, Assessment, Development, and Evaluation working-group approach. RESULTS We included 10 RCTs comprising 11,237 patients with TBI. Placebo showed higher mortality compared with that of a 2-g bolus of TXA (risk ratio, 1.53; 95% confidence interval, 1.08–2.17). Higher mortality was observed with a 1-g bolus of TXA followed by 1-g maintenance TXA compared with that of a 2-g bolus of TXA (risk ratio, 1.44; 95% confidence interval, 1.02–2.03). No significant differences in poor neurological outcomes or vascular occlusive events were observed between the treatment groups. CONCLUSION Placebo and a 1-g bolus followed by 1-g maintenance TXA were associated with higher mortality rates than those of a 2-g bolus of TXA. No difference in vascular occlusive events was observed with either treatment, indicating that our NMA recommends 2 g of TXA. However, the data for the 2-g bolus of TXA were from a single study, and further research is needed to draw definitive conclusions. LEVEL OF EVIDENCE Systematic Review/Meta-Analysis; Level III. Export
- 2 October 2024
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 85 (2) , 101-108
Tranexamic Acid in Pediatric Traumatic Brain Injury: A Multicenter Retrospective Observational Study
- 2 October 2024
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 85 (2) , 101-108
Tranexamic Acid in Pediatric Traumatic Brain Injury: A Multicenter Retrospective Observational Study
- Open Access
Reply to Sethuraman et al. Comment on “Utsumi et al. Differences in Pathophysiology and Treatment Efficacy Based on Heterogeneous Out-of-Hospital Cardiac Arrest. Medicina 2024, 60, 510”
We thank the authors of the Letter to the Editor for their astute points raised in reference to our original study
Open AccessReply to Sethuraman et al. Comment on “Utsumi et al. Differences in Pathophysiology and Treatment Efficacy Based on Heterogeneous Out-of-Hospital Cardiac Arrest. Medicina 2024, 60, 510”
We thank the authors of the Letter to the Editor for their astute points raised in reference to our original study